STAR-TREC is an international, multi-centre, randomised, phase II feasibility study comprising a 1:1:1 randomisation for eligible subjects with a small, clinically localised rectal cancer between;
- ARM A: Conventional TME surgery
- ARM B: Organ saving utilising long course concurrent chemoradiation
- ARM C: Organ saving utilising short course preoperative radiotherapy
A total of 120 patients will be randomised over 2 years.